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At the present, no anti-Hepatitis C virus (HCV) HCV vaccine is available, andmany patients failed the treat-
ment with new class of HCV inhibitors. In HCV infection, both experimental and clinic evidences indicate
that a strong CTL-immune response could have significant therapeutic effects.We developed an innovative
anti-HCV CD8+ T immunogen based on the uploading in engineered exosomes of full-length HCV-NS3 pro-
tein. HCV NS3 exosomes appeared immunogenic when injected in mice, as proven by the detection of a
memory CD8+ T lymphocyte pool twoweeks after the last of three immunizations. On the other hand, den-
dritic cells isolated fromPBMCs of HCV infected patients activate autologous HCVNS3-specific CD8+ T lym-
phocytes upon challenge with HCV NS3 exosomes. These results provide the proof-of-principle that
engineered exosomes can boost the CD8+ T cell immunity in HCV-infected patients, thus representing a
suitable option for patients resisting the therapies with recently discovered HCV inhibitors.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Although an effective new class of HCV NS3/NS4A and NS5B
inhibitors (i.e., boceprevir and sofosbuvir) is available [1], however
drug resistance, suboptimal activity against diverse HCV geno-
types, and their extremely high cost limit the expectancy of HCV
eradication, while prompting the research for innovative vaccine
strategies [2]. A both strong and broad CTL immune response tar-
geting cells expressing HCV antigens is expected to be a key step
towards viral clearance. In fact, the presence of multispecific IFN-
c producing, HCV-specific CD8+ T cells have been reproducibly
detected in infected hosts recovering from acute HCV infection
[3,4]. Consistently, in chronic HCV infection the functionality of
HCV-specific CD8+ T cells is significantly altered [5].
Exosomes are vesicles of 50–100 nm released constitutively by
all cell types [6]. They form intracellularly upon inward invagina-tion of endosome membranes. Leading to the formation of intralu-
minal vesicles which thereby form multivesicular bodies. They can
traffic either to lysosome vesicles or to the plasma membrane
thereby releasing their vesicular contents in the extra-cellular
milieu upon fusion with plasma membrane. Vesicles released by
this mechanism are defined exosomes.
Exosomes are nanoparticles having a low intrinsic immuno-
genic profile. Their immunogenicity is basically related to the
amounts and quality of antigens they incorporate. Exosomes have
been tested in a number of clinical trials demonstrating both feasi-
bility and good tolerance of exosomes as cell-free vaccines. How-
ever, the therapeutic efficacy appeared quite limited posing the
need for new methods to increase their immunogenicity.
Engineering exosomes to upload heterologous proteins repre-
sents the last frontier in terms of nanoparticle-based technology.
We optimized a method of protein incorporation in exosomes by
exploiting the unique properties of a non-functional mutant of
the HIV-1 Nef protein referred to as Nefmut. It incorporates at high
extents in exosomes meanwhile acting as carrier of protein anti-
gens fused at its C-terminus [7]. In this way, the Nefmut-based
fusion products remain protected from external behavior. These
features, together with the flexibility in terms of incorporation of
foreign antigens and ease of production, make Nefmut-based exo-
somes a convenient vehicle for immunogens.
v
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Fig. 1. Scheme of the pcDNA3-based vector expressing the Nefmut/NS3 fusion
protein. The positions of promoter (IE-CMV), Nefmut/HCV-NS3 fused open reading
frame, and poly A signal are signed. Base pair lengths of each moiety are also
indicated.
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Fig. 2. HCV NS3-specific immunity induced in mice by inoculation of Nefmut/NS3 exosom
(upper panels) or Nefmut/NS3 (lower panels). A total of 30 lg (for cell lysates) and 200 lU
with anti-Nef, anti-b-actin (for cell lysates only), and anti-ICAM-1 (for exosomes only) an
kDa. In addition, both exosome preparations were tested for CD63 contents (right panels
anti-CD63 mAb. Percentages of positive events are indicated. Results are representative
immune response in mice inoculated with either Nefmut-, Nefmut/NS3 exosomes, or reco
two weeks after the last inoculation, splenocytes were isolated and incubated 5 days in
Afterwards, cell activation extents were evaluated by IFN-c Elispot assay carried out in
5 ng/ml of PMA and 500 ng/ml of ionomycin. Shown are the mean + SD number of SFU/10
parametric Wilcoxon rank sum test.
106 S. Anticoli et al. / Trials in Vaccinology 5 (2016) 105–110HIV-1 Nef is a 27 kDa protein lacking enzymatic activities, how-
ever acting as a scaffold/adaptor element [8]. Nefmut lacks basically
all Nef functions [9], whereas incorporating in exosomes up to 100-
fold most efficiently than the wild-type isoform. Recently, we
showed that a viral TAA uploaded in Nefmut-based engineered exo-
somes is cross-presented in targeted APCs, thereby eliciting a
strong CTL immunity in mice which associates with clearing of
syngeneic tumor cells implanted after immunization [10]. In the
perspective to apply our previous findings to the treatment of
HCV infection, engineered exosomes uploading HCV NS3 were pro-es
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es. (A) Molecular characterization of exosome preparations uploading either Nefmut
equivalent of AchE activity of exosomes were assayed in western blot assays probed
tibodies. Arrows sign the relevant protein products. Molecular markers are given in
). Quadrants were set on the basis of the fluorescence of beads alone incubated with
of the assays performed on three different exosome preparations. (B) CD8+ T cell
mbinant NS3 protein. C57Bl/6 mice (5 per group) were inoculated three times and,
the presence or not of 5 lg/ml of either unrelated, Nef-, or NS3-specific peptides.
triplicate with 105 cells/well. As a control, untreated cells were also incubated with
5 cells. *p < 0.05. The paired Student’s t-test was used and confirmed using the non-
S. Anticoli et al. / Trials in Vaccinology 5 (2016) 105–110 107duced and tested for both their immunogenicity in mice and anti-
genicity in PBMCs from HCV infected patients.2. Materials and methods
2.1. Exosome production, purification, quantification, and
characterization
The recovery of the pcDNA3-based vector expressing the fusion
protein Nefmut/HCV-NS3, genotype 1b (Fig. 1) has been already
described [11]. Engineered exosomes were produced by transfect-
ing 293T cells as reported [7], and purified through differential
centrifugations [12]. Their amounts were measured in terms of
the activity of AchE, i.e., a classical exosome marker [13] through
the Amplex Red kit (Molecular Probes). Exosome preparations
were characterized by both western blot and FACS analysis as
reported [7]. For semi-quantitative western blot, scaled amounts
of recombinant Nef produced and quantified as described [14]
were included as reference samples.Isolation of PBMCs from either healthy donors or 
HCV infected patients
Monocyte isolation2.2. Mice immunization and detection of IFN-c producing CD8+ T
lymphocytes
All studies with animals here described have been approved by
the Ethical Committee of the Istituto Superiore di Sanità, Rome,
Italy (protocol n. 555/SA/2012) according to Legislative Decree
116/92 which has implemented in Italy the European Directive
86/609/EEC on laboratory animal protection. Animals used in our
research have been housed and treated according to the guidelines
inserted in here above mentioned Legislative Decree. C57Bl/6 mice
(Charles River Laboratories) were inoculated subcutaneously (s.c.)
3 times at 2-week intervals with either exosomes carrying Nefmut
and Nefmut/NS3, or recombinant NS3 genotype 1b (ProSpec). Two
weeks after the last inoculation, mice were sacrificed, and spleno-
cytes cultured with the following H-2b peptides: Nef48-56 TAAT-
NADCA [15], NS3370-377 ITQMYTNV, and NS3500-510 WYELTPAETSV
[16]. After 5 days of incubation, IFN-c Elispot assay was performed
in triplicate conditions using reagents from Mabtech AB. SFU were
counted 16 h later using an Elispot reader.Culture with either HCV-NS3 or 
unrelated peptides
GM-CSF+IL-4 on monocyte
cultures
iDC phenotyping
5 days
Exosome challenge
on iDCs
Co-culture in IFN-γ
ELISPOT microwells
IFN-γ ELISPOT assay
16 hours
CD8+ T cell selection
6 hours
Fig. 3. Flow of the experimental design leading to cross-presentation assay on
PBMCs from both healthy donors and HCV patients.2.3. Cross-presentation assay in human PBMCs
Selected HCV chronically infected subjects had an average age
of 51 years, were in good general health conditions, and did not
receive anti-HCV treatment in the last 3 years, to avoid confound-
ing results arising from the immunosuppressive effect of drugs.
The patients had average levels of ALT of 103 ± 32 U/L, and serum
HCV RNA mean titers of 2.7  106 IU/mL. PBMCs isolated from 3
chronically HCV infected patients and, as a control, 3 healthy
donors were cultured in RPMI, 10% AB human serum for 5 days
in the presence of PeptTivator NS3 (Miltenyi) (i.e., a pool of HCV
NS3 genotype 1b peptides consisting in 15-mers with 11 aa over-
lap covering the whole NS3 sequence) following the manufac-
turer’s recommendations. As a control, a mix of HIV-1 Gag
peptides including most frequent potential T epitopes (PTE) [17]
was used. In parallel, monocytes were separated from PBMCs using
anti-CD14 microbeads (Miltenyi), and differentiated to iDCs with
500 Units/mL of IL-4 (R&D Systems) and 30 ng/ml of GM-CSF (Ser-
otec Ltd). Their phenotype was routinely checked by FACS analysis
for the expression of CD11c and the absence of CD14 markers.
CD8+ T cells were separated from PBMCs using anti-CD8 microbe-
ads (Miltenyi). iDCs were challenged with the exosomes and, after
6 h of incubation, washed and co-cultured in triplicate conditions
at 1:2 ratio with the CD8+ T lymphocytes isolated from PBMC inan IFN-c Elispot microwell plate. After 16 h incubation, IFN-c Eli-
spot assay was performed, and SFU were counted.
2.4. Statistical analysis
When appropriate, data are presented as mean + SD. In some
instances, the paired Student’s t-test was used and confirmed using
the non-parametric Wilcoxon rank sum test. p < 0.05 was consid-
ered significant.
3. Results
3.1. HCV NS3 engineered exosomes elicit CD8+ T lymphocyte adaptive
immunity when injected in mice
Engineered exosomes uploading Nefmut/NS3 were characterized
compared to exosomes incorporating Nefmut alone in terms of the
contents of both Nefmut-related products and CD63, the latter being
a cellular marker typically associated to exosomes (Fig. 2A). We
noticed that the Nefmut/NS3 fusion product readily associated with
exosomes, even if apparently at slightly lower levels than Nefmut
alone. This decrease can be at least in part consequence of the
nearly 4-fold higher molecular weight of the fusion product com-
pared to Nefmut, which would lead to a steric hindrance in the pro-
cess of exosome incorporation.
The immunogenicity of the Nefmut/NS3 exosomes was tested in
C57Bl/6 mice by s.c. injections of amounts of exosomes incorporat-
ing 100 ng of the Nefmut/NS3 fusion protein, as assessed by semi-
quantitative western blot (not shown). Immunizations were
repeated three times at two week intervals. As controls, mice were
inoculated with exosomes uploading either 100 ng of Nefmut alone,
or the same amount of recombinant NS3. Two weeks after the last
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Fig. 4. Activation of HCV NS3-specific CD8+ T lymphocytes after challenge of autologous iDCs with Nefmut/NS3 engineered exosomes. A. Molecular characterization of
exosome preparations uploading VSV-G together with either Nefmut or Nefmut/NS3. A total of 200 lU equivalent of AchE activity of exosomes was assayed in western blot
assays probed with anti-Nef, anti-VSV-G, and anti-ICAM-1 antibodies. Arrows sign the relevant protein products. Molecular markers are given in kDa. In addition, both
exosome preparations were tested for CD63 contents (right panels). Quadrants were set on the basis of the fluorescence of beads alone incubated with anti-CD63 mAb.
Percentages of positive events are indicated. Results are representative of the assays performed on five different exosome preparations. B. Cross-presentation of NS3 delivered
by exosomes in iDCs from three chronically HCV infected patients. Following the scheme depicted on Fig. 2, 105 iDCs from both healthy and HCV-infected patients were
challenged with 100 lU equivalent of AchE activity of exosomes associating either Nefmut or Nefmut/NS3. After 6 h, the cells were put in co-culture overnight in IFN-c Elispot
microwells with CD8+ T lymphocytes purified from PBMCs cultivated for 5 days in the presence of either unspecific () or NS3 (+) specific peptides. Shown are the mean + SD
number of SFU/105 cells calculated from triplicate wells. *p < 0.05. The paired Student’s t-test was used and confirmed using the non-parametric Wilcoxon rank sum test.
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S. Anticoli et al. / Trials in Vaccinology 5 (2016) 105–110 109immunization,micewere sacrificed, and the splenocytes assayed for
the presence of both Nef- and NS3-specific CD8+ T lymphocytes by
culturing them for 5 days in the presence of either Nef- or NS3-
specific peptides. As controls, splenocytes were cultivated either in
complete medium, or in the presence of an unrelated peptide. By
IFN-c Elispot assay, we detected Nef-specific CD8+ T lymphocytes
within splenocytes frommice inoculated with exosomes uploading
either Nefmut or Nefmut/NS3. Most importantly, using either NS3-
specific peptides, we also detected the presence of NS3-specific
CD8+ T lymphocytes from mice inoculated with Nefmut/NS3
exosomes but not from those inoculatedwith Nefmut alone, whereas
neither Nef- nor NS3-specific immune responses were detected in
splenocytes from mice inoculated with recombinant NS3 (Fig. 2B).
These results indicate that exosomes uploading HCV-NS3 are
immunogenic.
3.2. Activation of HCV NS3 specific CD8+ T lymphocytes by autologous
iDCs challenged with HCV NS3 engineered exosomes
To investigate whether NS3 engineered exosomes are func-
tional in humans, PBMCs from HCV chronically infected patients
not under therapy and, as a control, healthy donors were isolated,
and purified monocytes were differentiated to iDCs. Meanwhile,
PBMCs were cultivated in the presence or not of a mix of peptides
spanning the whole NS3 sequence. As a control, a mix of HIV-1 Gag
peptides was used taking advantage from the fact that the selected
HCV patients were HIV-1 seronegative. After 5 days, iDCs were
challenged with the exosomes, and then put in co-culture with
CD8+ T lymphocytes isolated from the PBMC cultivated in the pres-
ence of peptides. Finally, iDCs/CD8+ T lymphocytes co-cultures
were carried out in IFN-c Elispot microwells for 24 h. A scheme
of this experimental design is reported in Fig. 3.
As already described [7], to optimize the sensitivity of the
cross-presentation assays, iDCs were challenged with exosomes
associating VSV-G. The molecular characterization of the exosome
preparations we used is shown in Fig. 4A. The co-expression of
VSV-G in exosome-producing cells seemed to favor the incorpora-
tion of the fusion product. In fact, differently to that observed for
exosomes produced in the absence of VSV-G (Fig. 2A), Nefmut and
Nefmut/NS3 appeared associated with exosomes at similar extents.
iDCs were challenged with either (VSV-G)Nefmut/NS3 or, as a con-
trol, (VSV-G) Nefmut engineered exosomes, and then co-cultivated
with autologous, peptide-stimulated CD8+ T lymphocytes in the
presence of either NS3 or, as a control, HIV-1 Gag peptide mixtures.
In view of the ascertained HIV-1 seronegativity of all donors, only
CD8+ T cells isolated from PBMCs from HCV infected patients and
cultured with the HCV-NS3 specific peptides would be activated
upon co-culture with the iDCs loaded with Nefmut/NS3. Indeed, as
shown in Fig. 4B, levels of activated lymphocytes significantly over
background were detected only in co-cultures from HCV infected
patients comprising iDCs challenged with Nefmut/NS3 exosomes
and CD8+ T lymphocytes isolated from PBMCs cultured with NS3-
specific peptides. The specificity of our assay was granted by the
absence of activation in CD8+ T lymphocytes isolated from PBMCs
of: (i) HCV patients cultured with irrelevant peptides, and (ii)
healthy donors stimulated with HCV-NS3 specific peptides.
These results indicate that exosomes engineered to upload HCV
NS3 efficiently activated NS3-specific memory CD8+ T lymphocytes
generated in patients as part of the immune response mounted
against HCV.
4. Discussion
We investigated whether the immunogenicity elicited by a viral
TAA delivered by Nefmut-based exosomes we previously described
[8] also applied to HCV-related antigens engineered in exosomes.The results we obtained from the immunogenicity assays we car-
ried out in mice proved that NS3-engineered exosomes can prime
and expand a NS3-specific CD8+ T cell immune response. Consider-
ing that exosomes have been produced in 293T human cells, it was
expected that they associated molecules of human origin which
would be represented at similar levels in both Nefmut and Nefmut/
NS3 exosomes. However, the NS3 expression in exosome-
producing cells would theoretically induce the uploading in exo-
somes of human products not represented in Nefmut control exo-
somes, thus eliciting an immune response representing a
potentially confounding factor. We believe that it was not the case
since we observed that, upon stimulation with unrelated peptides,
the activation extents of CD8+ T lymphocytes frommice inoculated
with Nefmut did not significantly differ from that observed in the
cells from mice injected with Nefmut/NS3 exosomes. On this basis,
evaluating the efficiency of the adaptive immune response elicited
by NS3-exosomes in an animal model of HCV infection, e.g., EFT-
Stat1/ mice [18], could be of interest. On the other hand, data
we obtained with PBMCs from HCV patients for the first time
demonstrate the CD8+ T cell antigenicity in ex vivo human primary
cells of the heterologous products uploaded in Nefmut-based engi-
neered exosomes. Considering that HCV NS3 is a quite conserved
protein, and the immune response elicited by Nefmut/NS3 exo-
somes is expected to be Class I MHC unrestricted in view of the
incorporation of the full-length protein, Nefmut/NS3 exosomes
might be considered a candidate for innovative anti-HCV therapeu-
tic strategies.
HCV-NS3 is considered an immunogen of election in several
ongoing anti-HCV vaccine protocols [reviewed in [19]]. For
instance, NS3 is expressed by both adenoviral- and MVA-based
vectors already proven to induce both potent and long-lasting
NS3-specific CD8+ T cell immunity. HCV-NS3 is also part of inacti-
vated Saccharomyces cerevisiae-based anti-HCV immunogens, and
DNA vectors expressing HCV-NS3 have been tested for their
immunogenicity upon injection by electroporation. In this scenar-
io, the here described anti-HCV vaccine strategy represents a start-
ing point for the development of both simple and innovative
immunization protocols having the potentiality to compete with
the most advanced anti-HCV therapeutic approaches.Conflicts of interest
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